Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know if TIL shrink s tumors in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. In this study, we are selecting a specific subset of white blood cells from the tumor that we thi

Trial Details

NCT ID
NCT01174121
Phase
PHASE2
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Pembrolizumab (Keytruda)
  • Fludarabine
  • Cyclophosphamide
  • Aldesleukin
  • Young TIL
Locations (sample)
  • Bethesda, Maryland, United States|38.98067,-77.10026

Key Eligibility Criteria

  • Measurable (per RECIST v1.0 criteria), metastatic cancer of one of the following types: upper or lower gastrointestinal, hepatobiliary, genitourina…
  • Confirmation of diagnosis of metastatic cancer by the NCI Laboratory of Pathology.
  • Refractory to approved standard systemic therapy. Specifically:
  • Patients with metastatic colorectal cancer must have received oxaliplatin or irinotecan.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →